Candidiasis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Candidiasis - Pipeline Review, H2 2016

Candidiasis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Candidiasis - Pipeline Review, H2 2016
Published Aug 10, 2016
151 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Candidiasis - Pipeline Review, H2 2016, provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Candidiasis
- The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
- The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Candidiasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-lic

  
Source:
Document ID
GMDHC8343IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Candidiasis Overview131
Therapeutics Development142
  Pipeline Products for Candidiasis Overview141
  Pipeline Products for Candidiasis Comparative Analysis151
Candidiasis Therapeutics under Development by Companies162
Candidiasis Therapeutics under Investigation by Universities/Institutes182
Candidiasis Pipeline Products Glance204
  Late Stage Products201
  Clinical Stage Products211
  Early Stage Products221
  Unknown Stage Products231
Candidiasis Products under Development by Companies243
Candidiasis Products under Investigation by Universities/Institutes271
Candidiasis Companies Involved in Therapeutics Development2822
  Amplyx Pharmaceuticals, Inc.281
  Bakker Medical Srl291
  Biomar Microbial Technologies301
  Biosergen AS311
  Cellceutix Corporation321
  Cidara Therapeutics, Inc.331
  Daewoong Pharmaceutical Co., Ltd.341
  Dermala Inc351
  General Biologicals Corporation361
  Grupo Ferrer Internacional, S.A.371
  Hsiri Therapeutics, LLC381
  iCo Therapeutics Inc.391
  Matinas BioPharma Holdings, Inc.401
  Nanomerics Ltd411
  Novabiotics Limited421
  NovaDigm Therapeutics, Inc.431
  Onxeo SA441
  Scynexis, Inc.451
  Sealife PHARMA GMBH461
  TGV-Laboratories471
  Viamet Pharmaceuticals, Inc.481
  Wellstat Vaccines, LLC491
Candidiasis Therapeutics Assessment5010
  Assessment by Monotherapy Products501
  Assessment by Combination Products511
  Assessment by Target522
  Assessment by Mechanism of Action542
  Assessment by Route of Administration562
  Assessment by Molecule Type582
Drug Profiles6074
  (clotrimazole + diclofenac sodium) Drug Profile601
  (clotrimazole + diclofenac sodium) 1 Drug Profile611
  61894700 Drug Profile621
  AC-17 Drug Profile631
  amphotericin B Drug Profile642
  amphotericin B Drug Profile663
  amphotericin B Drug Profile691
  Antibody to Target Ece1 for Candidiasis Drug Profile701
  APX-001 Drug Profile711
  arasertaconazole Drug Profile721
  BSG-005 Drug Profile731
  candidiasis vaccine Drug Profile741
  CD-101 Drug Profile753
  Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile781
  CTIX-1502 Drug Profile791
  Drug for Candidiasis Drug Profile801
  DWP-06081 Drug Profile811
  Forazoline A Drug Profile821
  iCo-010 Drug Profile831
  KSL-W Drug Profile841
  MH-010 Drug Profile851
  miconazole nitrate Drug Profile862
  Monoclonal Antibodies for Candidiasis Drug Profile881
  Monoclonal Antibody for Candidiasis Drug Profile891
  Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections Drug Profile901
  Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections Drug Profile911
  mutanobactins Drug Profile921
  Myc-102 Drug Profile931
  NDV-3 Drug Profile942
  NDV-3A Drug Profile961
  NP-339 Drug Profile971
  obliquumol Drug Profile981
  Occidiofungin Drug Profile991
  PAC-113 Drug Profile1002
  PMX-1408 Drug Profile1021
  PMX-1570 Drug Profile1031
  PMX-1576 Drug Profile1041
  PMX-1591 Drug Profile1051
  PMX-1625 Drug Profile1061
  PMX-519 Drug Profile1071
  PMX-70004 Drug Profile1081
  Recombinant Peptides for Oropharyngeal Candidiasis Drug Profile1091
  SCY-078 Drug Profile1103
  SLP-0901 Drug Profile1131
  SLP-0904 Drug Profile1141
  Small Molecule for Bacterial Vaginosis and Candidiasis Drug Profile1151
  Small Molecule for Fungal Infections Drug Profile1161
  Small Molecules for Aspergillosis and Candidiasis Drug Profile1171
  Small Molecules for Candidiasis Drug Profile1181
  Small Molecules for Candidiasis Drug Profile1191
  Small Molecules for Candidiasis Drug Profile1201
  Small Molecules for Fungal Infections Drug Profile1211
  Small Molecules for Fungal Infections Drug Profile1221
  Small Molecules for Systemic Candidiasis Drug Profile1231
  Synthetic Peptide to Inhibit CBL-B for Candidiasis Drug Profile1241
  Synthetic Peptides for Candidiasis Drug Profile1251
  Synthetic Peptides for Infections Diseases and Oncology Drug Profile1261
  TOL-463 Drug Profile1271
  Vaccine for Fungal Infections Drug Profile1281
  Vaccine to Target Ece1 for Candidiasis Drug Profile1291
  VT-1161 Drug Profile1304
Candidiasis Dormant Projects1344
Candidiasis Discontinued Products1381
Candidiasis Product Development Milestones13911
  Featured News &Press Releases1391
    Jun 20, 2016: SCYNEXIS Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections1391
    Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH1392
    Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections1411
    Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis1421
    Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 20161421
    Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors1431
    May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate1441
    May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors1451
    May 13, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Candida Infections1461
    Apr 15, 2016: SCYNEXIS Presents Data Supporting the Activity of its Lead Antifungal Drug Candidate SCY-078 Against Antifungal-resistant Candida Strains at the 13th ASM Conference on Candida and Candidiasis1461
    Apr 06, 2016: SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at 13th ASM Conference on Candida and Candidiasis1471
    Mar 10, 2016: Matinas BioPharma to Present an update on MAT2203 and to Present at the 28th Annual ROTH Conference1481
    Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis1481
    Feb 08, 2016: Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study With MAT2203 - Oral Encochleated Amphotericin B1491
Appendix1502
  Methodology1501
  Coverage1501
  Secondary Research1501
  Primary Research1501
  Expert Panel Validation1501
  Contact Us1501
  Disclaimer1511

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Candidiasis - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Candidiasis-Pipeline-Review-H2-2016-2088-16351>
  
APA:
Global Markets Direct - Market Research. (2016). Candidiasis - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Candidiasis-Pipeline-Review-H2-2016-2088-16351>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.